Repligen Corp. 10-Q Summary: Period Ended September 30, 2007
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for Repligen Corporation for the three and six-month periods ended September 30, 2007. Repligen is a biopharmaceutical company focused on developing novel therapeutics for central nervous system diseases and selling commercial products, specifically Protein A for monoclonal antibody purification and SecreFlo for pancreatic disorder assessment.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2007 | Six Months Ended Sep 30, 2007 |
|---|---|---|
| Total Revenue | $5,352,321 | $11,331,139 |
| Net Income | $40,306,077 | $40,546,056 |
| Net Gain from Litigation Settlement | $40,170,000 | $40,170,000 |
| Operating Income (Loss) | $40,770,099 | $40,755,162 |
| Cash and Cash Equivalents (Sep 30, 2007) | $38,415,731 | |
| Total Marketable Securities (Sep 30, 2007) | $24,280,366 | |
| Working Capital (Sep 30, 2007) | $60,509,845 | |
| Effective Tax Rate | 2% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 87% for the three months and 74% for the six months compared to the prior year periods. Product revenue grew 93% (three months) and 80% (six months), driven primarily by a 103% increase in Protein A sales volume.
- Profitability Shift: The company reported a net loss of $863,319 for the three months ended September 30, 2006, compared to net income of $40.3 million for the same period in 2007. This reversal is almost entirely attributable to a one-time litigation settlement gain.
- Operating Expenses: Excluding the litigation gain, operating expenses increased 20% (three months) and 39% (six months). Cost of product revenue rose 54% and 64% respectively, commensurate with higher production volumes. Selling, general, and administrative expenses increased due to litigation costs related to ongoing patent disputes.
- Liquidity: Cash and cash equivalents increased from $7.7 million at March 31, 2007, to $38.4 million at September 30, 2007, primarily due to the receipt of settlement proceeds.
Guidance, Outlook, and Risks
- Litigation Settlement: On September 10, 2007, Repligen and MIT settled a patent infringement lawsuit against ImClone Systems. ImClone paid $65 million, resulting in net proceeds of $40.17 million to Repligen after fees and MIT's share. This is a non-recurring item.
- Outlook: Management states that future revenue will be primarily limited to Protein A and SecreFlo sales. SecreFlo sales are expected to continue only through fiscal year 2009 due to supply limitations. The company is unable to reliably estimate when therapeutic product candidates will generate revenue.
- Risks: Key risks include the outcome of ongoing patent litigation against Bristol-Myers Squibb (trial scheduled for April 2008), dependence on third-party manufacturers, and the volatility of the biotechnology marketplace regarding capital raising.
- Capital Resources: Management believes current cash and investment balances are adequate to meet needs absent of acquisitions. Future capital requirements depend on clinical study success and R&D scope.
Investor Verification Checklist
- Sustainability of Earnings: Verify that the $40.17 million net gain is a one-time event and does not reflect core operating profitability.
- Customer Concentration: Note that the two largest customers accounted for 80% of product revenue for the six months ended September 30, 2007.
- SecreFlo Supply Chain: Confirm the timeline for SecreFlo sales, as the last shipment from the supplier was received in July 2007, with inventory expected to last only until fiscal 2009.
- Ongoing Litigation: Monitor the status of the patent infringement lawsuit against Bristol-Myers Squibb, which remains unresolved.
- Investment Portfolio: Review the composition of marketable securities, which includes auction rate securities, to understand liquidity risks.